Pediatric Chronic Anemia Medication
- Author: Susumu Inoue, MD; Chief Editor: Max J Coppes, MD, PhD, MBA more...
Medications are dictated by underlying disorders.
Chronic anemia due to intrinsic RBC abnormalities such as hemoglobinopathies, unstable hemoglobins, red cell membrane abnormalities, and red cell enzyme abnormalities do not warrant specific medications.
Nutritional anemia can be treated with supplements of deficient factors.
Recombinant erythropoietin has been useful in managing anemia related to chronic renal failure, rheumatoid arthritis, AIDS, and more recently in patients with DMT1 mutation. Hemoglobin levels and general feelings of well being have been much improved in patients since recombinant erythropoietin became commercially available.
These agents are essential for normal metabolism and DNA synthesis.
Vitamin B-12 (Ener-B, Twelve Resin-K)
This agent is used to treat megaloblastic anemia resulting from vitamin B-12 deficiency. Deoxyadenosylcobalamin and hydroxocobalamin are active forms of vitamin B-12 in humans. Vitamin B-12 synthesized by microbes but not humans or plants. Deficiency may result from intrinsic factor deficiency (pernicious anemia), partial or total gastrectomy, or diseases of the distal ileum. Deficiency initially and typically manifests as macrocytic anemia, although neurologic symptoms may be present. They can also cause confusion or delirium in elderly patients.
It is essential for normal erythropoiesis and is required for healthy neuronal function and normal function of rapidly growing cells.
These agents are useful for the treatment of iron deficiency anemia.
This is the mainstay treatment for patients with iron deficiency anemia. It is used as a building block for hemoglobin synthesis in treating anemia. It allows transportation of oxygen via hemoglobin and is necessary for oxidative processes of living tissue. Treatment should continue for about 2 months after correction of anemia and the etiological cause in order to replenish the body stores of iron. Ferrous sulfate is the most common and inexpensive form of iron used. Tablets contain 50-60 mg of iron salt. Other ferrous salts are used and may cause less intestinal discomfort because they contain smaller doses of iron (25-50 mg). Oral solutions of ferrous iron salts are available for use in pediatric populations.
Dietary iron deficiency anemia can be prevented by starting supplemental iron when infants are weaned off breast milk or regular formula at age 8-12 months.
The authors recommend 6 mg/kg/d of elemental iron for 6 months for infants and children with severe iron deficiency anemia. Please note the dose is based on the weight of elemental iron, not of iron salts.
Colony Stimulating Factors
These agents are used to manage anemia related to chronic renal failure, rheumatoid arthritis, and AIDS.
This is a purified glycoprotein produced from mammalian cells and modified with the gene coding for human erythropoietin (EPO). The amino acid sequence is identical to that of endogenous EPO. Its biological activity mimics human urinary EPO, which stimulates division and differentiation of committed erythroid progenitor cells and induces the release of reticulocytes from bone marrow into the blood stream.
Iron overload (usually from multiple transfusions) may require chelation therapy, which usually begins when the ferritin level is greater than 1000 ng/mL.
Deferoxamine is freely soluble in water. Approximately 8 mg of iron is bound by 100 mg of deferoxamine. Deferoxamine is excreted in urine and bile and discolors the urine red. It readily chelates iron from ferritin and hemosiderin but not from transferrin. It is most effective when provided to the circulation continuously by means of infusion. Deferoxamine may be administered by IM injection, slow infusion, SC bolus, or continuous infusion. It does not effectively chelate other trace metals of nutritional importance.
Deferasirox is available as a tablet for oral suspension. It is an oral iron-chelating agent demonstrated to reduce liver iron concentration in adults and children who receive repeated RBC transfusions. Deferasirox binds iron with high affinity in a 2:1 ratio. It is approved for treatment of treat chronic iron overload due to multiple blood transfusions. Treatment initiation is recommended when evidence of chronic iron overload (ie, transfusion of about 100 mL/kg packed RBCs [about 20 U for 40-kg person] and serum ferritin level consistently >1000 µg/L) is noted.
1,2 dimethyl-3-hydroxypyridine-4-one is a member of a family of hydroxypyridine-4-one (HPO) chelators that requires 3 molecules to fully bind iron (III), each molecule providing 2 coordination sites (bidentate chelation). Its half-life is approximately 2 hours. The inactive metabolite is predominantly excreted in urine. Deferiprone is indicated for transfusional iron overload caused by thalassemia syndromes when current chelation therapy is inadequate.
Dowling MM, Quinn CT, Plumb P, Rogers ZR, Rollins NK, Koral K. Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood. 2012 Nov 8. 120(19):3891-7. [Medline].
Baker C, Grant AM, George MG, Grosse SD, Adamkiewicz TV. Contribution of Sickle Cell Disease to the Pediatric Stroke Burden Among Hospital Discharges of African-Americans-United States, 1997-2012. Pediatr Blood Cancer. 2015 Dec. 62 (12):2076-81. [Medline].
Skeppner G, Kreuger A, Elinder G. Transient erythroblastopenia of childhood: prospective study of 10 patients with special reference to viral infections. J Pediatr Hematol Oncol. 2002 May. 24(4):294-8. [Medline].
Penchansky L, Jordan JA. Transient erythroblastopenia of childhood associated with human herpesvirus type 6, variant B. Am J Clin Pathol. 1997 Aug. 108(2):127-32. [Medline].
Prassouli A, Papadakis V, Tsakris A, Stefanaki K, Garoufi A, Haidas S. Classic transient erythroblastopenia of childhood with human parvovirus B19 genome detection in the blood and bone marrow. J Pediatr Hematol Oncol. 2005 Jun. 27(6):333-6. [Medline].
Iolascon A, Camaschella C, Pospisilova D, Piscopo C, Tchernia G, Beaumont C. Natural history of recessive inheritance of DMT1 mutations. J Pediatr. 2008 Jan. 152(1):136-9. [Medline].
Global Burden of Disease Pediatrics Collaboration, Kyu HH, Pinho C, et al. Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. JAMA Pediatr. 2016 Mar 1. 170 (3):267-87. [Medline].
Henderson S, Timbs A, McCarthy J, Gallienne A, Van Mourik M, Masters G. Incidence of haemoglobinopathies in various populations - the impact of immigration. Clin Biochem. 2009 Dec. 42(18):1745-56. [Medline].
Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med. 2012 Sep. 2(9):a011692. [Medline].
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010 Jun 3. 115(22):4331-6. [Medline].
Baker RD, Greer FR. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics. 2010 Nov. 126(5):1040-50. [Medline].
Wiseman DH, May A, Jolles S, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood. 2013 Jul 4. 122 (1):112-23. [Medline]. [Full Text].
Iolascon A, De Falco L. Mutations in the gene encoding DMT1: clinical presentation and treatment. Semin Hematol. 2009 Oct. 46(4):358-70. [Medline].
Finberg KE. Iron-refractory iron deficiency anemia. Semin Hematol. 2009 Oct. 46(4):378-86. [Medline].